At a glance
ClinicalIndex Comparison RecordPhase 2Active· 9 enrolled
Drug / intervention
IMG-7289drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)
The University of Texas Health Science Center at San Antonio·interventional·Posted Sep 9, 2019·Updated Sep 10, 2025
In Brief
A Phase 2 clinical trial evaluating IMG-7289 for Thrombocythemia, Essential. Active but no longer recruiting, targeting 9 participants across 1 site.
Detailed Summary
This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombocythemia, Essential
CountriesUnited States
Timeline
Phase 2Active
20202021202220232024202520262027
First PostedSep 2019
Enrollment StartApr 2020
Primary CompletionDec 2023
TodayJul 2026
Study CompletionDec 2026
First PostedSep 9, 2019
Enrollment StartApr 9, 2020
Primary CompletionDec 20, 2023
Study CompletionDec 20, 2026
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.8 years ago
Interventions
IMG-7289drug
Single starting dose with individualized dose titrations throughout